Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is…
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and…
Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has…
Clarivate Epidemiology's coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
Immune checkpoint inhibitors have greatly altered the treatment landscape for urothelial carcinoma. Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo…
Immune checkpoint inhibitors have greatly altered the treatment landscape for urothelial carcinoma. Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…
Epi Data Slicer